NCT05908071

Study Evaluating SHEN26 Capsule in Patients With Mild to Moderate COVID-19

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of SHEN26 Capsule in Adult Participants With Mild to Moderate COVID-19

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,200 (estimated)
• Sponsor: Shenzhen Kexing Pharmaceutical Co., Ltd. · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, double-blind, placebo-parallel-controlled phase III clinical trial. It is designed to evaluate the efficacy and safety of SHEN26 capsules in Chinese adult patients with mild to moderate COVID-19

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	SHEN26 capsule	Capsule administered orally after meals.
DRUG	SHEN26 placebo	Capsule administered orally after meals.

Timeline

• Start date: 2023-05-13
• Primary completion: 2024-05-01
• Completion: 2024-07-01
• First posted: 2023-06-18
• Last updated: 2023-06-22

Locations

1 site across 1 country: China